This protocol is designed to assess immunotherapeutic redirected T-cell (CAR T-cell) cytotoxicity against 3D structured cancerous cells (spheroids) in real time.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
This protocol is designed to assess immunotherapeutic redirected T-cell (CAR T-cell) cytotoxicity against 3D structured cancerous cells (spheroids) in real time.
Immunotherapy has become a field of growing interest in the fight against cancer otherwise untreatable. Among all immunotherapeutic methods, chimeric antigen receptor (CAR) redirected T cells obtained the most spectacular results, in particular with pediatric B-acute lymphoblastic leukemia (B-ALL). Classical validation methods of CAR T cells rely on the use of specificity and functionality assays of the CAR T cells against target cells in suspension and in xenograft models. Unfortunately, observations made in vitro are often decoupled from results obtained in vivo and a lot of effort and animals could be spared by adding another step: the use of 3D culture. The production of spheroids out of potential target cells that mimic the 3D structure of the tumor cells when they are engrafted into the animal model represents an ideal alternative. Here, we report an affordable, reliable and easy method to produce spheroids from a transduced colorectal cell line as a validation tool for adoptive cell therapy (exemplified here by CD19 CAR T cells). This method is coupled with an advanced live imaging system that can follow spheroid growth, effector cells cytotoxicity and tumor cell apoptosis.
Adoptive cell transfer (ACT) represents the next generation cancer treatment. It relies on the injection of effector cells (T- or NK-cells) into a patient. These cells can be genetically modified with a receptor that will guide them to their target, the tumor, and destroy it. Recently this approach was shown to be feasible when a Chimeric Antigen Receptor (CAR) directed against the B-cell marker CD19 was introduced into the patient T cells to kill his/her cancer1. In the case of CAR, which is an artificial receptor, the design consists of specific antibody fragments, the antigen binding domain reduced to an entity designated single chain variab....
Access restricted. Please log in or start a trial to view this content.
1. Generation of Spheroids from Colorectal Cancer Cell Line
Access restricted. Please log in or start a trial to view this content.
As can be seen in Figure 1, it is crucial to check by flow cytometry the level of expression of CD19 CAR on T cells (Figure 1A) and the level of CD19 on HCT116 tumor cell lines (Figure 1B). Figure 2 exemplifies the outcome of a typical spheroid experiment. The automated imaging apparatus takes pictures in four different channels: bright field, phase, green and red fluore.......
Access restricted. Please log in or start a trial to view this content.
The use of spheroids as an innovative tool to validate future cancer treatment has become a field of growing interest in the past years. Spheroids represent an intermediate step between classical 2D in vitro analysis and in vivo assessment. The method further holds a lot of promise regarding their potency in terms of tumor micro-environment mimicking as well as gene profiling7. The protocol presented in this publication was adapted from Saheen et al.11 to the Incuc.......
Access restricted. Please log in or start a trial to view this content.
The authors have nothing to disclose.
This work was supported by the Norwegian Research Council under Grants #244388, #254817 and #284983; the Norwegian Cancer Society (#6829007); The Norwegian Health Region South East under Grant #17/00264-6 and #2016006.
....Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| Dulbecco’s Phosphate Buffered Saline | SIGMA-ALDRICH | D8537-500ML | Lot Number: RNBG7037 |
| 75 cm² growth area flasks | VWR | 430639 | Lot Number: 2218002 |
| 75 cm² growth area flasks | VWR | 734-2705 | Lot Number: 3718006 |
| Trypsin-EDTA | SIGM-ALDRICH | T3924-100ml | Lot Number: SLBTO777 |
| RPMI 1640 med L-glutamin, 10 x 500 mL | Life Technology (Gibco) | 21875-091 | Lot Number: 1926384 |
| Fetal Bovine Serum | Gibco | 10500064 | Lot Number: 08Q3066K |
| Gentamicin | Thermo Fischer | 15750060 | Lot Number: 1904924A |
| Trypan Blue Solution, 0.4% | Thermo Fischer | 15250061 | Lot Number: 1886513 |
| 96 well plate, round bottom | VWR | 734-1797 | Lot Number: 33117036 |
| Dynabeads Human T-Activator CD3/CD28 | Thermo Fischer | 11132D | - |
| X-VIVO 15 with Gentamicin L-Gln, Phenol Red, 1 L | BioNordika | BE02-060Q | Lot Number: 8MB036 |
| CTS Immune Cell Serum Replacement | Thermo Fischer | A2596102 | Lot Number: 1939319 |
| IL-2 Proleukin | Novartis | Lot Number: 505938M | |
| IncuCyte Annexin V Red Reagent | Essen Bioscience | 4641 | Lot Number: 17A1025-122117 |
| Reagent Reservoir | VWR | 89094-672 | Lot Number: 89094-672 |
| 15 mL tubes | VWR | 734-1867 | Lot Number: 19317044 |
| anti-human CD19-PE | BD Biosciences | 555413 | Lot Number: 4016990 RRID: AB_395813 |
| Biotin-SP (long spacer) AffiniPure F(ab')2 Fragment Goat Anti-Mouse IgG | Jackson ImmunoResearch | 115-066-072 | Lot Number: 129474: RRID: AB_2338583 |
| Streptavidin-PE | BD Biosciences | 554061 | Lot Number: 5191579: RRID: AB_10053328 |
| HCT 116 Colorectal Carcinoma Line | ATCC | CCL-247 | - |
| Incucyte S3 | Essen Bioscience |
Access restricted. Please log in or start a trial to view this content.